Business of Biotech catches up with Celyad Oncology’s Filippo Petti on his company's differentiated approach to the discovery and development of allogeneic CAR-T cell therapy candidates for the treatment of cancer. Petti shares how the company intends to scale in-house manufacturing in its Belgium-based facility. Listen now and subscribe so you never miss an episode.
By Maura C. Kibbey, Ph.D., U.S. Pharmacopeia (USP)
Some of the new COVID-19-targeted vaccines are spurring the use of novel analytical technologies to support rapid and thorough characterization, which may help pave the way for other vaccine manufacturers to implement these technologies as well.